The collaboration covers Stoke's SYNGAP1 preclinical program, as well as preclinical programs for Rett syndrome and an undisclosed neurodevelopmental target.
Under the terms of the collaboration, Stoke will receive $60 million in upfront payment, up to $907 million in potential milestone payments, as well as royalties on future sales from Acadia.
Acadia shares were 2.8% lower while Stoke shares were down 3.6% in morning trading.
Price: 21.97, Change: -0.62, Percent Change: -2.74
|Street Color: Global Calendar For Week Ending May 20|
|Ryder System Receives $4.4 Billion Cash Buyout Propo...|
|Payoneer Shares Rally After Q1 Beats Expectations, 2...|
|Market Chatter: Alibaba Group's Venture in Russia Re...|
|Research Alert: CFRA Raises View On Paycom Software ...|